NCT05504915View on ClinicalTrials.gov

Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseColitis, Ulcerative
Trial Locations (1)

31000

Klinički bolnički centar Osijek (University Hospital Center Osijek), Osijek

All Listed Sponsors
collaborator

Josip Juraj Strossmayer University of Osijek

OTHER

lead

Osijek University Hospital

OTHER